Roivant Sciences (ROIV) vs Viatris (VTRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Roivant Sciences (ROIV) has outperformed Viatris (VTRS) over the past year, gaining 115.6% versus a gain of 72.5%. Over five years, ROIV leads with a +477.2% price change compared with +29.9% for VTRS. Roivant Sciences is the larger company by market cap ($24.81 billion vs $19.96 billion), about 1.2 times the size, while Viatris is growing revenue faster (-3.0% vs -71.6%).
Viatris pays a dividend yielding 2.76%, while Roivant Sciences does not currently pay one. Viatris converts more of its revenue into profit, with a net margin of -24.6% versus -3629.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ROIV | VTRS |
|---|---|---|
| Share price | $34.35 | $17.38 |
| Market cap | $24.81B | $19.96B |
| 1-day change | -1.15% | -0.66% |
| YTD return | +60.14% | +40.48% |
| 1-year return | +115.57% | +72.49% |
| 5-year return | +477.24% | +29.94% |
| Forward P/E | — | 6.50 |
| EPS (TTM) | $-0.53 | $-0.36 |
| Dividend yield | 0.00% | 2.76% |
| Annual dividend | $0.00 | $0.48 |
| Revenue (latest FY) | $8.26M | $14.30B |
| Revenue growth (YoY) | -71.57% | -2.98% |
| Net income (latest FY) | $-299.77M | $-3.51B |
| Gross margin | — | 35.06% |
| Operating margin | -6235.69% | -18.62% |
| Net margin | -3629.19% | -24.58% |
| 52-week high | $42.50 | $18.43 |
| 52-week low | $15.90 | $9.69 |
| Distance from 52-week high | -19.18% | -5.72% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +39.97% | +13.38% |
| Average volume | 7.02M | 9.18M |
| Shares outstanding | 722.32M | 1.15B |
| Employees | 721 | 30,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ROIV has outperformed VTRS by 43.1 percentage points over the past year.
- Viatris offers a meaningfully higher dividend yield (2.76% vs 0.00%).
- Viatris is more profitable, keeping -24.6 cents of every revenue dollar as net income versus -3629.2 cents for Roivant Sciences.
- Viatris grew revenue faster in its latest fiscal year (-2.98% vs -71.57%).
About Roivant Sciences
ROIV stock →Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 721 employees
About Viatris
VTRS stock →Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 30,000 employees
ROIV vs VTRS FAQ
Which is bigger, Roivant Sciences or Viatris?
Roivant Sciences (ROIV) is larger, with a market capitalization of $24.81B compared with $19.96B for Viatris (VTRS).
Which stock has performed better over the past year, ROIV or VTRS?
ROIV returned +115.57% over the past 12 months, compared with +72.49% for VTRS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Roivant Sciences or Viatris?
Viatris pays a dividend yielding 2.76%, while Roivant Sciences does not currently pay a regular dividend.
Are Roivant Sciences and Viatris in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.